We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Guangdong Fapon Biotech Co., Ltd.

Download Mobile App




Hidden Genetic Subgroup Sheds New Light on Brain Tumors

By LabMedica International staff writers
Posted on 23 Jan 2026

Meningiomas are the most common primary tumors of the central nervous system and are typically treated with surgery or radiation, as targeted therapies remain limited. More...

They account for more than one-third of all brain tumors and affect over 39,000 people in the United States each year. However, unpredictable behavior in a subset of meningiomas complicates diagnosis and treatment planning, and despite extensive study, approximately 17% lack known genetic drivers. New findings have now identified a previously unrecognized molecular subgroup of meningiomas, offering clinicians additional insight that may support more informed treatment decisions.

The discovery was made by a multidisciplinary team at Yale University (New Haven, CT, USA) spanning neurosurgery, genomics, computational biology, and pathology. The newly identified subgroup is driven by fusions in the FOS gene family, which includes FOSB, a protein that regulates cell reproduction, separation, and transformation in humans. These findings were reported in a study recently published in Nature Communications. 

The researchers compiled genomic profiles from 1,232 meningioma cases across previously published datasets to assess how FOS/FOSB fusion–driven tumors fit within the broader molecular landscape. The analysis showed that FOS/FOSB fusion–positive cases form a distinct molecular cluster with unique biological features. Histopathologic evaluation was then performed to define the tumors’ morphologic characteristics and integrate the molecular findings into a unified diagnostic and clinical framework. 

This work expands the current molecular classification of meningiomas and addresses a major gap in understanding tumors that lack known key genetic alterations. Identification of this fusion-defined subgroup provides new insight into meningioma development and lays the groundwork for future studies aimed at improving diagnostic precision and uncovering subtype-specific vulnerabilities that could inform targeted therapies.     

“One of the driving motivations for the study is the fact that there is currently no systemic or targeted treatment for these tumors,” said Zeynep Erson-Omay, PhD, assistant professor in the Department of Neurosurgery at Yale School of Medicine. “Treatments have proved difficult to develop, so we hope that discovering these new subsets can pave the way for new treatments.” 

“The alteration we’ve identified is not unique to meningiomas,” added Dr. Erson-Omay. “There are other soft-tissue and bone-tissue tumor types that have similar genetic alterations. Our hope is that any treatments developed from these findings can have a broader impact beyond just meningiomas.”

Related Links:
Yale School of Medicine


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
βeta-Hydroxybutyrate Reagent
β-Hydroxybutyrate LiquiColor®
New
Gold Member
Fully-auto Specific Protein (Nephelometry) Analyzer
PA240
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: New evidence now questions whether a single stool-test cutoff should be applied uniformly across all age groups.(Photo courtesy of Paul Maguire - Adobe Stock)

Study Questions Uniform Stool-Test Cutoff Across Age Groups

Colorectal cancer remains a major clinical challenge, ranking as the fourth most common cancer and the second-leading cause of cancer death in the U.K. Early-onset colorectal cancer, defined as diagnosis... Read more

Immunology

view channel
Image: The findings underscore the importance of aligning allergy testing with clinical history and diagnostic guidelines to reduce inappropriate testing and its consequences (Image Credit: iStock)

Survey Finds Gap Between Food Allergy Testing Awareness and Clinical Practice

Food allergy evaluation can be challenging when laboratory results do not match clinical symptoms. Broad food allergy panels may detect sensitization without confirming an actual allergy, potentially leading... Read more

Industry

view channel
Image

Labcorp Partners With Grupo Fleury to Expand Clinical Trial Operations in Brazil

Multinational clinical trials require laboratory partners that combine global expertise with local operational capabilities. Brazil is an important clinical research destination, supported by its diverse... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.